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In 2012, blood, skin and soft tissue infections caused 
by clindamycin resistant Streptococcus pyogenes 
(group A streptococcus; GAS) appeared to be increas-
ing in the Helsinki metropolitan area. We compared 
monthly percentages of clindamycin resistant iso-
lates in the area between 2012 and 2013, with those 
in 2010 and 2011. Resistance frequency in terms of 
patient age was also studied. We reviewed the medi-
cal records of bacteraemic cases in 2012 and 2013 and 
linked the data to emm types. To inform on the emm 
distribution among GAS isolated from skin and soft 
tissue infections during the epidemic, GAS isolates 
of one month (March 2013) were emm typed. For GAS 
blood, skin, and soft tissue isolates taken together, 
the proportions of clindamycin resistant isolates were 
significantly higher in 2012 and 2013 (23% and 17%, 
respectively) compared with the two previous years 
(3%, p<0,001). The erythromycin resistance percent-
ages were almost equal to clindamycin (22% and 17%) 
in 2012 and 2013, respectively. Clindamycin resist-
ance was most frequent in GAS isolates of 40 to 60 
year-old patients (148/417; 36%). Among clindamycin 
resistant isolates, 12 of 14 blood isolates from 2012 to 
2013, and 11 of 13 skin and soft tissue isolates from 
March 2013, were emm33. Emm33 GAS bacteraemia 
was associated with clindamycin and erythromycin 
resistance (odds ratio (OR): 7.0; 95% confidence inter-
val (CI): 1.9–25.3). Infection focus was mainly the skin; 
either cellulitis (7/12) or necrotising fasciitis (3/12). 
All emm33 GAS isolates harboured the ermTR resist-
ance gene with constitutive macrolides, lincosamides 
and streptogramines B (MLSB) phenotype. Emm33 GAS 
was responsible for the higher proportion of clindamy-
cin resistance in skin, soft tissue, and blood isolates 
locally in 2012 and 2013.
Introduction
Streptococcus pyogenes (group A streptococcus; GAS) 
causes pharyngitis, skin and soft tissue infections, 
and invasive septic diseases [1]. Certain GAS emm 
types have been associated with tissue-specific infec-
tions [2], antibiotic resistance [3], and local epidem-
ics [3]. Erythromycin resistance has been linked to 
various emm types, such as 4, 6, 12, 75, and 77 [4-7]. 
Most of these emm types have been identified in throat 
isolates.
Depending on the erythromycin resistance mechanism, 
isolates may also be resistant to clindamycin, although 
relatively rarely [8].
There is limited information concerning clindamycin 
resistance in GAS isolates causing skin and soft tis-
sue infections. In Finland, the annual percentages of 
erythromycin and clindamycin resistance was only 2 
to 3% in 2012 when all GAS isolates (including throat 
isolates) were analysed together [9]. The figures for all 
GAS isolates have been the same also in Helsinki met-
ropolitan area [10]. In February 2013, while making the 
annual local antibiotic resistance statistics of 2012, a 
high proportion of clindamycin resistance was noticed 
among blood, skin and soft tissue GAS isolates.
In this study, we investigated whether a specific emm 
type was behind this phenomenon, by examining the 
laboratory data of GAS isolates in 2012 and 2013 in the 
Helsinki metropolitan area. We used baseline data of 
years 2010 and 2011 for comparison. The invasive GAS 
cases of 2012 and 2013 were analysed in detail and 
linked to emm types (blood isolates) to characterise 
common denominators behind the increase in clinda-
mycin resistance. To obtain more information on the 
emm distribution in GAS isolates from skin and soft 
tissue infections, emm typing was performed on a set 
of such GAS isolates obtained during March 2013 in the 
Helsinki metropolitan area.
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Methods
Setting
In Finland, the Division of Clinical Microbiology at 
HUSLAB is a clinical diagnostic laboratory that serves 
the Helsinki metropolitan area of ca 1.5 million popu-
lation. It receives from the local laboratories all blood 
cultures flagged positive for bacteria by the BacT/
ALERT3D system (bioMerieux, Marcy l’Etoile, France) 
for bacterial identification and resistance analyses. The 
GAS blood isolates are routinely stored and sent to the 
national reference laboratory at the National Institute 
for Health and Welfare for emm typing. HUSLAB does 
the final identification and resistance analyses also for 
all other GAS isolates e.g. throat, skin, and soft tissue 
isolates of the Helsinki metropolitan area and keeps 
records of the resistance data for statistical analyses, 
however the bacterial isolates are not routinely stored. 
For this study, GAS isolates of skin and soft tissue 
infections of March 2013 were collected specifically, 
and stored at -70 °C. This was done to characterise the 
emm type distribution of both clindamycin suscepti-
ble and resistant GAS isolates from skin and soft tis-
sue infections (while the epidemic was still going on), 
and to verify if the distribution was the same in these 
isolates compared with the routinely stored blood iso-
lates. We were able to gather 78% (45/58) of the total 
skin and soft tissue GAS isolates of the month.
Microbiological methods
At HUSLAB GAS isolates are routinely identified by 
colony morphology with betahaemolysis on sheep 
blood agar and Lancefield grouping with latex agglu-
tination (Latex Reagent A, Oxoid Ltd, Basingstoke, 
Hants, England). The resistance for erythromycin and 
clindamycin is routinely determined using the double-
disc diffusion method on Mueller-Hinton agar with 5% 
defibrinated horse blood with 20 mg/L beta-NAD (MH-F 
broth). In this study, additional minimum inhibitory 
concentrations (MICs) were determined for the clinda-
mycin resistant skin and soft tissue GAS isolates of 
March 2013 and blood isolates of 2012 to 2013 after 
twice sub-culturing on horse blood agar. MICs were 
determined by Etests (bioMerieux SA, Marcy l’Etoile, 
France) for azithromycin, clindamycin, doxycycline, 
erythromycin, levofloxacin, moxifloxacin, tetracycline, 
and vancomycin, on Mueller-Hinton (MH)-F broth using 
0.5 McFarland inoculum and incubated for 18 ± 2h 
with 5% CO2 at 35 ± 1 °C. Telithromycin susceptibility 
was tested by disc-diffusion method in similar condi-
tions as in MIC determinations. European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) 2013 
breakpoints were used to determine whether the zone 
inhibitions or MICs were considered susceptible (S), 
intermediate (I) or resistant (R).
Emm typing and resistance gene analysis of the 
collected group A streptococcus isolates
At the National Institute for Health and Welfare, the 45 
GAS isolates of March 2013 and 109 blood GAS isolates 
from 2012 to 2013 were emm typed according to the 
guidelines provided by Centres for Disease Control and 
Prevention (http://www2a.cdc.gov/ncidod/biotech/
strepblast.asp) as previously described [11].
DNA of the erythromycin and clindamycin resistant 
GAS isolates (blood isolates of 2012–2013; n = 14 and 
isolates of March 2013; n = 13) was extracted by sus-
pending the colonies in 100 µl of TE buffer and boiling 
for 15 min, followed by centrifugation at 13,000 rpm for 
2 min. The presence of erm, including ermB and ermTR, 
and mefA genes was detected by multiplex-polymerase 
chain reaction (PCR) including primers for amplification 
of mefA, ermB and ermTR genes, as described previ-
ously [12]. Positive controls were S. pyogenes A569 for 
mefA, Escherichia coli with plasmid pJIR229 for ermB, 
and S. pyogenes A200 for ermTR [13].
Susceptibility data analysis
The susceptibility analyses of clinical isolates were 
made using WHONET 5.6 software. We analysed the 
resistance figures of GAS isolates of the Helsinki met-
ropolitan area between January 2012 and December 
2013, and compared the data to the baseline years, 
namely 2010 and 2011. Blood, skin, and soft tissue 
isolates were analysed separately from throat isolates. 
One isolate per patient, the most resistant one, was 
included in the analysis (WHONET definition). Data 
were expressed as percentage of isolates resistant 
or intermediate for erythromycin together and as per-
centage of isolates resistant for clindamycin, accord-
ing to the EUCAST 2013 standard (http://www.eucast.
org). The reason for this was that the standard did not 
include a zone diameter breakpoint for intermediate 
Figure 1
Percentage of skin, soft tissue, and blood group A 
streptococcus isolates showing reduced susceptibility to 
clindamycin and erythromycin in Helsinki metropolitan 
area, Finland, 2012–2013 (n = 1,765)
Clinda R%: percentage of isolates considered resistant to 
clindamycin according to European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) 2013 breakpoints; Ery R+I%: 
percentage of isolates considered intermediate-resistant 
and resistant to erythromycin, according to EUCAST 2013 
breakpoints.
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for clindamycin, but for erythromycin it did. Inducible 
clindamycin resistance was detected by antagonism 
of clindamycin activity by erythromycin (the D phe-
nomenon) and if not present the isolate was reported 
susceptible. In HUSLAB the detected antagonism was 
reported resistant for clindamycin.
Analysis of clinical data and statistics
Electronic medical records of patients with a GAS posi-
tive blood culture between January 2012 and December 
2013 in Helsinki metropolitan area were reviewed to 
identify underlying conditions and any common expo-
sure between the patients. Age, sex, C-reactive protein 
(CRP) value, and leucocyte count at the time of diagno-
sis were registered. Diagnosed diabetes was recorded. 
Alcohol abuse was defined as a known social or medi-
cal problem caused by alcohol noted in the medical 
records. Intravenous drug abuse was registered simi-
larly when mentioned in the records. Suspected focus 
of infection was registered. Presence of a cutaneous 
infection was described as either cellulitis (infections 
of the skin and underlying tissues such as erysipelas 
and deeper non-necrotising soft-tissue infection) or 
necrotising fasciitis (progressive, destructive, subcuta-
neous streptococcal infection with necrosis observed 
either directly or under surgery). Need for surgical pro-
cedures, complications, and stay at an intensive care 
unit due to GAS bacteraemia was recorded. Mortality 
within seven days after GAS positive blood culture was 
recorded. Data were analysed and compared using 
Fisher’s exact or Pearson chi-squared tests, or t-test, 
Mann–Whitney U-test or analysis of variance (ANOVA), 
when appropriate, using SPSS for Windows statisti-
cal package (SPSS Inc., Chicago, IL). Logistic regres-
sion analysis was used to identify the risk factors. A 
p-value < 0.05 was considered statistically significant.
Results
Resistance data of clinical group A 
streptococcus isolates
When the resistance data were analysed without throat 
isolates, the proportions of skin, soft tissue, and blood 
GAS isolates obtained from Helsinki metropolitan 
area that were clindamycin resistant in 2012 and 2013 
were respectively 23% (199/866) and 17% (153/899). 
The baseline figures were 3% (22/745) in 2010 and 
3% (24/734) in 2011 (p < 0,001; 2012 and 2013 figures 
compared with 2010 and 2011 figures). The proportions 
of erythromycin intermediate-resistant and resistant 
isolates were almost equal to those for clindamycin, 
namely 22% (191/866) and 17% (152/899) in 2012 and 
2013, respectively. Baseline proportions of erythro-
mycin intermediate-resistant and resistant isolates 
were 4% (26/745) and 5% (33/734) in 2010 and 2011 
(p < 0,001; 2012 and 2013 figures compared with 2010 
and 2011 figures), respectively.
The increase in proportion of isolates with clindamycin 
resistance began in the spring 2012 and was the high-
est at 49% (40/82) in October 2012 (Figure 1).
At the end of the study period, in December 2013, still 
12% (10/81) of skin, soft tissue, and blood GAS isolates 
were clindamycin resistant. The proportion of clinda-
mycin resistant isolates varied between age groups, 
and was highest in the 41 to 50 (35%; 84/238) and 51 
to 60 year-olds (36%; 64/179), and lowest among those 
< 16 years of age (2%; n = 12/569; Figure 2).
The proportion of clindamycin resistant throat isolates 
remained at the baseline level being 3% (233/8,953), 
and 4% (354/9,083) in 2012 and 2013, respectively. 
The proportion of throat isolates which were interme-
diate-resistant or resistant to erythromycin were also 
Figure 2
Clindamycin susceptibility of skin, soft tissue, and blood 
group A streptococcus isolates by age group, Helsinki 
metropolitan area, Finland, 2012–2013 (n = 1,765)
Clinda R: resistant to clindamycin; Clinda S: susceptible to 
clindamycin.
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Figure 3
Emm type distribution of invasive group A streptococcus 
isolates, Helsinki metropolitan area, Finland, 2012–2013 
(n = 109)
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3% (278/8,953) and 4% (391/9,083) in 2012 and 2013, 
respectively.
Emm types, clindamycin resistance, and 
clinical data of invasive group A streptococcus 
cases in 2012 and 2013
A total of 109 GAS positive blood isolates were identi-
fied in the Helsinki metropolitan area between January 
2012 and December 2013. Figure 3 shows the emm type 
distribution of these invasive isolates.
Of the 109 GAS positive blood isolates, 14 were clin-
damycin resistant and these included 12 emm33, one 
emm28, and one emm89. Figure 4 shows the time dis-
tribution of the invasive GAS isolates resistant or sen-
sitive for clindamycin with respective resistance genes. 
None of the emm33 isolates were susceptible for clin-
damycin. During the baseline years 2010 and 2011, 
when clindamycin resistance among isolates was at a 
low level, no invasive emm33 GAS were isolated in the 
Helsinki metropolitan area.
Table 1 compares the clinical data of emm33 cases to 
the cases with another emm type. In logistic regression 
analysis clindamycin and erythromycin resistance, 
alcoholism, and intravenous drug abuse (Table 1) asso-
ciated with emm33 GAS bacteraemia. Of the 12 emm33 
cases, 10 had infection focus on the skin or soft tis-
sue. Three emm33 cases underwent a surgical proce-
dure due to complications of GAS infection. There were 
no re-infections or need for intensive care in emm33 
cases.
Emm types and laboratory referral data of skin 
and soft tissue group A streptococcus isolates 
of March 2013
A total of 45 GAS isolates from skin and soft tissue 
infections were gathered in March 2013 and emm 
typed. Emm typing revealed two isolates being 
S. dysgalactiae subsp. equisimilis and these were dis-
carded from the analysis. The remaining 43 isolates 
represented emm types shown in Figure 5. Of these, 
13 showed clindamycin resistance and these included 
11, which were emm33. None of the emm33 were sus-
ceptible for clindamycin. Ten emm33 isolates were from 
a skin lesion or abscess as shown by the laboratory 
referral data in Table 2.
Figure 4
Time distribution of invasive group A streptococcus isolates, Helsinki metropolitan area, 2012–2013 (n = 109)
Clinda S: isolates susceptible to clindamycin.
Clindamycin resistant isolates with respective resistance genes are shown separately (all emm33 (n =12), one emm89, and one emm28).
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Susceptibility and resistance genes of the 
collected emm33 group A streptococcus isolates
All studied emm33 GAS (skin and soft tissue isolates 
of March 2013 and blood isolates of 2012–2013, totally 
n = 23) showed the constitutive macrolides, lincosa-
mides and streptogramines B (MLSB) phenotype with 
similar antibiotic resistance profiles and harboured 
the ermTR resistance gene. The isolates were non-sus-
ceptible for azithromycin (MIC range: 12– > 256 mg/L), 
clindamycin (all MICs > 256 mg/L), and erythromycin 
(MIC range: 2–8 mg/L). They showed susceptibility for 
doxycycline (MIC range: 0.125–0.38 mg/L), levofloxacin 
(MIC range: 0.25–0.75 mg/L), moxifloxacin (MIC range: 
0.064–0.19 mg/L), tetracycline (MIC range: 0.25–1.0 
mg/L), and vancomycin (MIC range: 0.38–0.75 mg/L). 
All isolates were susceptible for telithromycin (disc-
diameter range: 27–38mm), which was tested by disc-
diffusion method.
Discussion
During 2012 and 2013 emm33 GAS caused a local epi-
demic of skin and soft tissue infections in the adult 
population in Helsinki metropolitan area, Finland. The 
outbreak was detected as a marked increase in the pro-
portion of isolates resistant to erythromycin and clin-
damycin. In most cases the primary infection focus was 
the skin, but a few GAS emm33 infections were invasive 
and caused necrotising fasciitis. All emm33 isolates 
were resistant to both erythromycin and clindamycin.
There was an association of emm33 with alcohol 
and intravenous drug abuse, however the number 
of patients was very low so these results have to be 
interpreted with caution. Alcohol abuse was marked 
positive if mentioned in the patient records. Since 
alcoholism is not always evident and not even always 
actively asked about by the doctor in the hospital, this 
information is most probably partly lacking from our 
data. The same counts for intravenous drug abuse. An 
association with alcohol abuse has nevertheless been 
reported for certain other emm types, such as emm59 
and emm1 [14,15].
Emm33 belongs to the emm superfamily group D, 
which includes emm types causing skin infections, 
such as impetigo [2,16]. Emm33 has further been char-
acterised as a member of the D4 emm-cluster, which 
is able to bind plasminogen [17]. Plasminogen binding 
may contribute to the skin tissue tropism by possible 
break down of tissue barriers facilitating dissemination 
and prolonged bacterial persistence in the skin [18]. 
There is limited data concerning infections caused by 
this emm type. It caused some of the severe GAS infec-
tions of intravenous drug users reported in a study in 
the United Kingdom (UK) in 2003 and 2004, but was 
Table 1
Invasive emm33 cases compared with invasive non-emm33 cases, Helsinki metropolitan area, Finland, 2012–2013 (n = 109)
Emm33 Non-emm33 P OR (95%CI)
Number of cases (male/female) 12 (7/5) 97 (47/50) NS –
Age in years: mean (range) 54 (22–80) 51 (0–89) NS –
C-reactive protein in mg/L: mean (range) 164 (4–393) 189 (4–573) NS –
Leucocyte count: mean (range) 13 (4–26) 14 (1–39) NS –
Cases with alcohol abuse: n/N 8/12 17/97 < 0.001 11.9 (2.9–49.7)
Cases with intravenous drug abuse: n/N 4/12 5/97 < 0.01 9.1 (2.0–40.8)
Cases with erythromycin resistant isolatesa: n/N 12/12 2/97 < 0.001 7.0 (1.9–25.3)
Cases with clindamycin resistance: n/N 12/12 2/97 < 0.001 7.0 (1.9–25.3)
Cases with cellulitis: n/N 7/12 41/97 NS –
Cases with necrotising fasciitis: n/N 3/12 4/97 NS –
Cases with diabetes: n/N 3/12 18/97 NS –
7-day mortality: n/N 0/12 4/97 NS –
CI: confidence interval; OR: odds ratio; NS: not significant, p > 0.05.
a  Including intermediate-resistant and resistant isolates, according to EUCAST 2013 breakpoints.
Figure 5
Emm type distribution of skin and soft tissue group 
A streptococcus isolates, Helsinki metropolitan area, 
Finland, March 2013 (n = 43)
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not the most common emm type in that study [19]. 
Intravenous drug abuse has been shown to be a risk 
factor for severe disease caused by GAS [20].
GAS is able to cause very local and timely limited epi-
demics, as shown in intravenous drug users in the UK 
[19]. Interestingly, in 2012 in our neighbouring country, 
Sweden, there was an increase of invasive emm1 GAS 
diseases occurring mostly in patients over 80 years of 
age [21]. The invasive emm1 numbers have remained 
stable in Helsinki metropolitan area between 2010 and 
2013 indicating that the Swedish epidemic is local or 
has not reached Finland yet.
The Finnish National Institute for Health and Welfare 
receives all invasive GAS isolates from Finland for 
genotyping and strain collection. Since 2007, the main 
genotyping method has been emm typing. In Finland, 
the first emm33 invasive GAS isolates were found only 
in 2012 and they all originated from the Helsinki metro-
politan area. From June 2013 onwards sporadic emm33 
cases have been found also in other hospital districts, 
however emm33 still remains an uncommon genotype 
in Finland (Pieter Smit, personal communication, April 
2014).
Several mechanisms underlie the macrolide and lin-
cosamide resistance. M phenotype isolates carry the 
mefA gene, which causes efflux of the antibiotic and 
confers resistance to many macrolides with preserved 
susceptibility to clindamycin and streptogramin B 
[22]. Emm4 GAS with mefA has previously caused 
high erythromycin resistance locally in Finland [23]. 
Interestingly, in our study none of the tested isolates 
carried the mefA resistance gene. The resistance data 
of the Helsinki metropolitan area showed also that 
most of the isolates with decreased susceptibility to 
erythromycin were also clindamycin resistant (either 
with inducible or constitutive phenotype) suggesting 
that the M phenotype was not generally present in the 
GAS isolates during the years 2012 to 2013.
Ribosomal methylation of the target of the antibiotics 
(ermA, ermB or ermTR) prevents binding of the antibiot-
ics by causing a conformational change in the 23S ribo-
some [24]. The ermB isolates usually show constitutive 
MLSB (cMLSB) resistance to macrolides, clindamycin, 
and streptogramin B, while the ermA and ermTR iso-
lates may show macrolide-induced resistance to clin-
damycin [13]. In our study all emm33 isolates shared 
the ermTR macrolide resistance gene with a cMLSB 
resistance phenotype. This resistance phenotype is 
more common among ermB but has in rare occasions 
also been shown by isolates carrying the ermTR gene 
[25].
All the emm33 isolates were also susceptible to tel-
ithromycin. Usually isolates with the cMLSB phenotype 
are resistant or intermediate to telithromycin, however, 
such phenotypes harbour typically the ermB gene [26]. 
Accordingly, two isolates in our study (a blood emm89 
and a skin isolate of March 2013 emm11) with cMLSB 
phenotype with ermB gene showed intermediate sus-
ceptibility to telithromycin (data not shown). In con-
trast, an isolate with inducible MLSB phenotype with 
ermB (skin isolate of March 2013 emm92) was sus-
ceptible for telithromycin. The only isolate with induc-
ible MLSB phenotype with ermTR gene (a blood isolate 
emm28) was susceptible for telithromycin, as were 
all the emm33 isolates. Similar results have shown 
Giovanetti et al. regarding inducible ermTR GAS iso-
lates [27]. All the emm33 isolates in our study showed 
large disc-diameters growth suppression by telithro-
mycin. Unfortunately at the time of investigation, tel-
ithromycin Etests were not available in our laboratory, 
so we were not able to determine MICs, which would 
have represented more precise data.
The emm33 isolates in our study were also tetracycline 
susceptible, while Kataja et al. showed that inducible 
ermTR GAS isolates in Finland in 1994 and 1995 were 
mostly tetracycline resistant [25]. To fully understand 
the resistance mechanism underlying emm33, the iso-
lates should be examined in more detail. The fact that 
Table 2
Laboratory referral data of the group A streptococcus 
isolates from skin and soft tissue that were clindamycin 
resistant, Helsinki metropolitan area, Finland, March 2013 
(n = 13)
Sex Age groups in years
Emm 
type
Resistance 
gene Infection focus
Female 81–90 33 ermTRa Decubital wound, sacrum
Male 31–40 33 ermTRa Auricular canal
Male 41–50 33 ermTRa Suppurative wounds, foot and elbow
Female 31–40 33 ermTRa
Postoperative 
wound infection, 
gynaecological
Female 51–60 33 ermTRa Postoperative wound infection, ankle
Male 41–50 33 ermTRa Abscess, finger
Male 17–30 33 ermTRa Impetigo, perioral
Male 41–50 33 ermTRa Postoperative wound infection, finger
Female 17–30 33 ermTRa Abscess, leg
Female 31–40 33 ermTRa Nasal discharge
Male 17–30 33 ermTRa Impetigo, foot
Male 17–30 92 ermBb Suppurative wound, heel
Male 61–70 11 ermBc Penile sores
a Constitutive ermTR.
b Inducible ermB.
c Constitutive ermB.
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emm33 isolates had the same resistance gene and 
similar antibiotic resistance patterns supports the idea 
that they belong to the same clone (Pieter Smit, per-
sonal communication, April 2014).
Clindamycin is an important drug in the primary health-
care, especially, as it is used for treating GAS infections 
in penicillin allergic patients. The skin and soft tissue 
infections of intravenous drug abusers and of diabetic 
patients are often polymicrobial with anaerobic bacte-
ria and staphylococci present making clindamycin the 
drug of choice for empirical treatment. In invasive, sep-
tic GAS infections clindamycin is used in combination 
with penicillin for better outcome possibly diminish-
ing the bacterial toxin production [28]. Spreading of a 
skin-tropic emm type with clindamycin resistance is of 
concern considering the empirical antibiotic treatment 
of the abovementioned patient groups. An announce-
ment, aimed at the primary care and hospital doctors 
of the city of Helsinki, was released in spring 2013 
by HUSLAB together with the infectious disease spe-
cialists of the Helsinki city hospitals concerning the 
proportion of clindamycin resistant GAS figures. It 
guided the empirical therapy of adult skin infections 
recommending that clindamycin should not have been 
used as monotherapy. The infectious disease special-
ists of the whole Helsinki metropolitan area were also 
informed, and additional antimicrobial susceptibility 
testing was conducted for the clindamycin resistant 
GAS isolates to find alternative drugs for penicillin-
allergic patients. Surveillance of the situation is impor-
tant because emm33 GAS may spread to children since 
it is a potential impetigo-causing emm type [2].
The study shows that for resistance statistics it is 
important to analyse skin and soft tissue GAS sepa-
rately from the numerous throat GAS. Different emm 
types are typical for distinct anatomical locations and 
important resistance phenomena may be masked if iso-
lates are analysed only together. Here we documented 
a single, local, epidemic of a previously rare emm33 
GAS causing skin and soft tissue infections with also 
invasive cases. This emm type caused rapid changes 
in macrolide and clindamycin resistance locally in the 
adult population. These findings had an impact on the 
empirical treatment of skin and soft tissue infections 
of the area.
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